Home > Newsletters > Devices & Diagnostics Letter > Experts: Early Collaboration With FDA Critical To Aligning Drug-Dx Approvals
Devices & Diagnostics Letter
Aug. 27, 2012 | Vol. 39 No. 34
Experts: Early Collaboration With FDA Critical To Aligning Drug-Dx Approvals
Companies developing companion drugs and in vitro diagnostics (IVD) should hold joint meetings with CDRH and the Center for Drug Evaluation and Research (CDER) as early as possible and ensure that drug and diagnostic development timelines are aligned, Linda Burdette, director of regulatory affairs at Hoffmann-La Roche, said Tuesday at the Cambridge Health Institute’s Regulatory Compliance in Drug-Diagnostic Co-Development conference.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.